

CURRICULUM VITAE

Name: Damian Wild	
Present appointment: <i>(Job title, department, and organisation.)</i>	
Professor of Nuclear Medicine, Division Head of Nuclear Medicine, Head Center of Neuroendocrine- and Endocrine Tumors Department of Radiology Division of Nuclear Medicine University Hospital Basel	
Address: <i>(Full work address.)</i>	
University Hospital Basel Division of Nuclear Medicine Petersgraben 4 CH-4031 Basel Switzerland	
Telephone number:	Email address:
++41 61 328 66 83	Damian.wild@usb.ch
Qualifications:	
<ul style="list-style-type: none"> - 2011: PhD, Division of Medicine, University College London, UK Supervisor: Prof. P.J. Ell and Prof. M.E. Caplin - 2009: Swiss Medical Association, Certificate of Completion of Training in Nuclear Medicine (Facharzt für Nuklearmedizin FMH) - 2004: MD thesis, University of Basel, Switzerland Supervisor Prof. H. Mäcke 	
Professional registration:	
<ul style="list-style-type: none"> - 2009: Federal State of Baden-Württemberg, Board of Registration in Medicine - 2009: Swiss Medical Association (FMH) 	
Previous and other appointments: <i>(Include previous appointments in the last 5 years and other current appointments.)</i>	
<ul style="list-style-type: none"> - 2015 – present: Full Professor of Nuclear Medicine, University Basel, Switzerland - 2014 – present: Head Center of Neuroendocrine and Endocrine Tumors, University Hospital Basel, Switzerland - 2012 – 2015: Tenure Track Assistant Professor of Nuclear Medicine, University of Basel, Switzerland - 2012 – present: Division Head of Nuclear Medicine, University Hospital Basel, Switzerland - 2009 – 2011: Consultant in Nuclear Medicine, University Hospital Freiburg, Germany, Medical Director: Prof. W.A. Weber - 2008 – 2009: Research Fellow in Gastroenterology, Neuroendocrine Tumor Unit, Royal Free Hospital NHS Trust, London, Clinical lead and head: Prof. M.E. Caplin - 2004 – 2008: Residency in Nuclear Medicine, University Hospital Basel, Switzerland, Medical Director: Prof. J. Müller-Brand - 2003 – 2004: Residency in Nuclear Medicine, University Hospital Zürich, Switzerland, Medical Director: Prof. G.v. Schulthess 	
Research experience: <i>(Summary of research experience, including the extent of your involvement. Refer to any specific clinical or research experience relevant to the current application.)</i>	
<ul style="list-style-type: none"> - Coordinating investigator of 1 prospective multicentre clinical Phase I/II therapy study - Primary investigator of 4 prospective clinical Phase I/II imaging studies - Primary investigator of 3 prospective clinical Phase 0 proof of principle studies - Co-investigator/sponsor representative of 1 prospective clinical Phase I therapy study - Co-investigator of 1 prospective multicenter clinical Phase III imaging study 	

- Co-investigator/sponsor representative of 1 prospective clinical Phase III imaging study
- Co-investigator/sponsor representative of 2 prospective clinical Phase 0 proof of principle studies

Research training: (*Details of any relevant training in the design or conduct of research, for example in the Clinical Trials Regulations, Good Clinical Practice, consent or other training appropriate to non-clinical research. Give the date of the training.*)

- 2012: CH-GCP-training: University Hospital Basel, Clinical Trial Unit, 2012

Relevant publications:

- 63.** Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, Merkle E, Zech CJ, Boll D, Vogt DR, Gloor B, Christ E*, **Wild D***. Comparison of Glucagon-like Peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localization of occult Insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study: *Eur J Nucl Med Mol Imaging* 2018;45:2318-27
- 61.** Sauter A, Mansi R, Hassiepen U, Muller J, Panigada T, Wiehr S, Wild AM, Geistlich S, Behe M, Rottenburger C, **Wild D**, Fani M. Targeting of the cholecystokinin-2 receptor with the minigastrin analog ¹⁷⁷Lu-PP-F11N: does the use of protease inhibitors further improve in vivo distribution. *J Nucl Med* 2018:[Epub ahead of print]
- 59.** Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, **Wild D**. Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. *J Nucl Med* 2018;59:915-21
- 56.** Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, **Wild D**. Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. *J Nucl Med* 2018;59:909-14
- 51.** Nicolas G, Mansi R, McDougall L, Kaufmann J, Bouterfa H, **Wild D**, Fani M. Biodistribution, pharmacokinetics and dosimetry of ¹⁷⁷Lu-, ⁹⁰Y- and ¹¹¹In-labelled somatostatin receptor antagonist OPS201 in comparison to the agonist ¹⁷⁷Lu-DOTATATE: the mass effect. *J Nucl Med* 2017; 58:1435-41
- 47.** Baumann T, Rottenburger C, Nicolas G, **Wild D**. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging. *Best Practice & Research Clinical Endocrinology & Metabolism* 2016;30:45-57
- 39.** Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E*, **Wild D***. Localization of hidden Insulinomas with ⁶⁸Ga-DOTA-exendin-4 PET/CT: A Pilot Study. *J Nucl Med* 2015;56(7):1075-8
- 38.** Christ E*, **Wild D***, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Bear HU, Perren A, Reubi JC. Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT. *Endocrine* 2015;50(3):821-3
- 35.** **Wild D**, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JEF, Reubi JC, Mäcke HR, Weber WA. Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy (PRRT): A Pilot Study. *J Nucl Med* 2014;55 (8):1248-1252
- 31.** Christ E*, **Wild D***, Ederer S, Behe M, Nicolas G, Caplin ME, Brändle M, Clerici Th, Fischli S, Stettler C, Eil PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F. GLP-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. *Lancet Diabetes & Endocrin* 2013;1(2):115-122
- 30.** **Wild D**, Bomanji JB, Benkert P, Maecke H, Eil PJ, Reubi JC, Caplin ME. Comparison of ⁶⁸Ga-DOTA-NOC and ⁶⁸Ga-DOTA-TATE PET/CT within Patients with Gastroenteropancreatic Neuroendocrine Tumors. *J Nucl Med* 2013;54(3):364-72
- 26.** **Wild D**, Fani M, Behe M, Brink I, Rivier JEF, Reubi JC, Maecke HR, Weber WA. First Clinical

Evidence that Imaging with Somatostatin Receptor Antagonists is feasible. **J Nucl Med** 2011;52:1412-7

25. Wild D*, Christ E*, Caplin ME, Kurzwinski TR, Forrer F, Brändle M, Seufert J, Weber WA, Bomanji J, Perren A, Ell PJ, Reubi JC. Glucagon-like peptide-1 vs. somatostatin receptor targeting reveals two distinct forms of malignant insulinomas. **J Nucl Med** 2011;52:1073-8


24. Wild D, Frischknecht M, Zhang H, Morgenstern A, Buchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR. Alpha- vs. Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (^{213}Bi -DOTA-PESIN and ^{213}Bi -AMBA versus ^{177}Lu -DOTA-PESIN). **Cancer Research** 2011;71(3):1009-18.

21. Pattou F, Kerr-Conte J, **Wild D**. GLP-1 receptor scanning for imaging of human beta cells transplanted in muscle. **N Engl J Med** 2010;363(13):1289-90.

16. Wild D, Maecke HR, Christ E, Gloor B, Reubi J.-C. Glucagon-like peptide-1 receptor scans to localize occult insulinomas. **N Engl J Med** 2008;359(7):766-8.

* These authors contributed equally to this work

Total of 66 papers in peer reviewed journals with a total impact factor of more than 300

Signature:	Date:
	10.12.2018